HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

KYS 05090

a T-type calcium channel blocker; structure in first source

Also Known As:

KYS-05090; KYS05090

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - KYS 05090: 4

Experts

1.	Lee, Jae Yeol: 4 articles (07/2014 - 07/2008)
2.	Cho, Sehyeon: 3 articles (07/2014 - 12/2013)
3.	Lee, Kyung-Tae: 3 articles (07/2014 - 12/2013)
4.	Rim, Hong-Kun: 3 articles (07/2014 - 12/2013)
5.	Choi, Doo Li: 2 articles (03/2014 - 12/2013)
6.	Choi, Hye-Eun: 2 articles (03/2014 - 12/2013)
7.	Jang, Sun Jeong: 2 articles (03/2014 - 12/2013)
8.	Rhim, Hyewhon: 2 articles (12/2013 - 07/2008)
9.	Cho, Young-Wuk: 1 article (07/2014)
10.	Choi, Jung-Hye: 1 article (07/2014)

Related Diseases

1.	Adenocarcinoma of Lung 07/08/2014 - "In this study, KYS05090 induced autophagy- and apoptosis-mediated cell death in human lung adenocarcinoma A549 cells. " 03/15/2014 - "The MTT assay results indicated that BK10040 was cytotoxic against human lung adenocarcinoma (A549) and pancreatic cancer (MiaPaCa2) cells in a dose-dependent manner with IC50 of 2.25 and 0.93μM, respectively, which is ca. 2-fold more potent than lead compound KYS05090 despite of its decreased T-type calcium channel blockade. "
2.	Ovarian Neoplasms (Ovarian Cancer) 12/15/2013 - "Herein, a series of new 3,4-dihydroquinazoline derivatives were synthesized via a brief SAR study on KYS05090 template and evaluated for both T-type Ca(2+) channel (Cav3.1) blockade and cytotoxicity on three human ovarian cancer cells (SK-OV-3, A2780 and A2780-T). "
3.	Neoplasms (Cancer) 12/15/2013 - "With respect to cell cycle arrest effect on A2780 and A2780-T cells, KYS05090 induced large proportion of sub-G1 phase in the cell cycle progression of A2780 and A2780-T, meaning the induction of cancer cell death instead of cell cycle arrest via blocking T-type Ca(2+) channel. " 07/08/2014 - "It has been reported that [3-(1,1'-biphenyl-4-yl)-2-(1-methyl-5-dimethylamino-pentylamino)-3,4-dihydroquinazolin-4-yl]-N-benzylacetamide 2hydrochloride (KYS05090), a selective T-type Ca2+ channel blocker, reduces tumor volume and weight in the A549 xenograft model, but the molecular mechanism of cell death has not yet been elucidated. " 07/15/2008 - "As a result, KYS05090, a most potent T-type Ca(2+) channel blocker, was found to be as potent as doxorubicin against some human cancer cells without acute toxicity. "
4.	Pancreatic Neoplasms (Pancreatic Cancer) 03/15/2014 - "The MTT assay results indicated that BK10040 was cytotoxic against human lung adenocarcinoma (A549) and pancreatic cancer (MiaPaCa2) cells in a dose-dependent manner with IC50 of 2.25 and 0.93μM, respectively, which is ca. 2-fold more potent than lead compound KYS05090 despite of its decreased T-type calcium channel blockade. "
5.	Lung Neoplasms (Lung Cancer) 07/08/2014 - "Our findings suggest that KYS05090 has potential chemotherapeutic value for the treatment of lung cancer. "

Related Drugs and Biologics

1.	Mibefradil
2.	T-Type Calcium Channels (T-Type Calcium Channel)
3.	Paclitaxel (Taxol)
4.	Doxorubicin (Adriamycin)
5.	diphenyl (biphenyl)
6.	BK10040